Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ANKK1	255239	BUPROPION	CHEMBL894		PharmGKB
ANKK1	255239	OLANZAPINE	CHEMBL715		PharmGKB
ANKK1	255239	RISPERIDONE	CHEMBL85		PharmGKB
ANKK1	255239	ALCOHOL	CHEMBL545		PharmGKB
ANKK1	255239	NEMONAPRIDE	CHEMBL20734		PharmGKB
ANKK1	255239	ARIPIPRAZOLE	CHEMBL1112		PharmGKB
ANKK1	255239	CLOZAPINE	CHEMBL42		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ANKK1	rs1800497	AA	methadone	"dosage","metabolism/PK"	yes		Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	21902500	827816336
ANKK1	rs1800497	A	Drugs used in nicotine dependence	efficacy	no	An association between this SNP and response to nicotine replacement therapy was not found. Cannot access full-text with subject numbers and details, but authors mention that this is a larger cohort with greater statistical power, and that the results contradict their earlier finding of an association.	Allele A is not associated with response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.	19273465	769172985
ANKK1	rs4938013	C	clozapine	efficacy	no	Drug response was assessed using Clinical Global Impressions - Improvement (CGI-I) scores. Patients were classified as responders (CGI-I score of 1 or 2) or non-responders (CGI-I score greater than 3). The C allele was more frequently observed in non-responders than in responders, but the association was not significant after correction for multiple testing.	Allele C is not associated with response to clozapine in people with Schizophrenia as compared to allele A.	22722500	981502629
ANKK1	rs1800497	A	lithium	efficacy	not stated	This is from a review article which does not give all the details. It says that no association was found between the SNP and lithium response, but it does not state exactly how the alleles were compared.	Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele G.	21047205	699639221
ANKK1	rs1800497	AA + AG	aripiprazole	efficacy	yes	A1/A1 (AA) vs A2/A2 (GG) and A1/A2 (AA) vs A2/A2 were statistically significant for PANSS positive score (positive symptoms). Assumed TaqA1 = allele A, TaqA2 = allele G, though the specific alleles were not reported in this study.	Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG.	18926547	769250889
ANKK1	rs1800497	AA + AG	bupropion	efficacy	no	Meta-analysis includes 5 studies. 225 subjects with the AA and AG genotype of 567 participants (39.7%) and 289 subjects with the GG genotype of 703 par- ticipants (41.1%) succeeded in smoking cessation. An influence of this Taq1A polymorphism on smoking cessation treatment with bupropion was not observed (OR = 0.893; 95% CI 0.705 – 1.132).	Genotypes AA + AG are not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotype GG.	25881752	1449713140
ANKK1	rs1800497	A	risperidone	efficacy	yes		Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.	18855532	613979290
ANKK1	rs1800497	A	antipsychotics	efficacy	no	in a meta-analysis.	Allele A is not associated with response to antipsychotics in people with Schizophrenia as compared to allele G.	20194480	769168986
ANKK1	rs2587550	G	haloperidol	efficacy	no	When in a haplotype with rs1003641 A allele, as compared to rs1003641 G allele. Response assessed by Positive and Negative Symptoms Scale (PANSS) score after 1 month of treatment. Patients with the G-A haplotype had a greater decrease in PANSS score compared to those with the A-G haplotype. Statistical significance was set at 0.008 using the false discovery method (FDR). Please note alleles for this SNP have been complemented to the plus chromosomal strand.	Allele G is associated with increased response to haloperidol in people with Schizophrenia as compared to allele A.	22893251	1183491878
ANKK1	rs1800497	A	methadone	dosage	no	Methadone maintenance dose was not associated with genotype of the SNP but it was correlated to the highest dose ever used. Multiple doses versus single dose, body weight, history of cocaine dependence and ethnicity (Asian>Caucasian>African) were independently associated with methadone dose in multiple regression analysis.	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.	25556837	1444695427
ANKK1	rs1800497	AA + AG	bupropion	efficacy	no	Cessation success required patients to complete 6 months of smoking abstinence confirmed by end-expiratory exhaled carbon monoxide. There was no difference in success rate between genotype groups when looking over all patients, patients in the varenicline group, or the bupropion and varenicline group.	Genotypes AA + AG are not associated with response to bupropion in people with Tobacco Use Disorder as compared to genotype GG.	26153084	1446765784
ANKK1	rs1800497	A	bupropion	efficacy	no	The A variant was not identified as a predictors of prolonged abstinence (outcome measure) at treatment end or at 6 month follow-up. Only within the G carrier, SLC6A3-9 repeat genotype is associated with a higher abstinence rate (p<0.03).	Allele A are not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele G.	14570538	1449713146
ANKK1	rs7118900	AA + AG	methadone	dosage	no	This association was statistically significant after permutation analysis based on 40,000 replicates, but not statistically significant after adjusting for testing for multiple SNPs (Bonferroni correction). Note; this association may be linked to the association with rs2283265 in the DRD2 gene.	Genotypes AA + AG are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	23651024	982032521